Abivax Shares Surge 27% at the Opening of the Paris Stock Exchange
French biotech company Abivax saw its shares soar by 27.07% Monday morning, crossing the threshold of 125.80 euros, while the CAC 40 index fell by 0.55%. This movement occurs in a context of accelerated consolidation within the inflammatory bowel disease sector, where major global pharmaceutical companies are looking to secure cutting-edge oral assets.
Long-Term Momentum
The dynamics of the stock are part of a longer-term movement. Over seven days, Abivax has recorded a rise of 9.39%, while its quarterly performance shows a +59.04%. This rapid morning increase should be viewed in the context of the stock's dizzying annual trajectory, which has peaked at +1,844% since the beginning of 2025, a substantial difference from the broader market's twelve-month performance of +11.91%. However, exchanges remain cautious, with only 0.19% of the capital traded, reflecting a certain restraint from investors despite the displayed volatility. The monthly volatility of 28.75% and a beta of 0.15 highlight the significant gap between Abivax's movements and those of the CAC 40, positioning this stock well beyond the ordinary fluctuations of the general market.
Technical Perspective
From a technical standpoint, the stock is poised to test its resistance zone at 122.40 euros, which it has just surpassed. The 50-day moving average, set at 101.53 euros, remains significantly behind, confirming the recent upward trend but also the rapidity of the progression that creates a structural gap. The Relative Strength Index (RSI), positioned at 53, remains neutral and does not indicate an immediate overextension signal. The Bollinger Bands frame the movement between 90.20 euros at the bottom and 127.34 euros at the top, suggesting that the stock is approaching its upper volatility limit.
A More Nuanced View of Underlying Flows
A more nuanced reading of the underlying flows reveals certain tensions. The OBV (On-Balance Volume) shows a negative value, while the CMF (Chaikin Money Flow) is at -0.11, hinting at a discrepancy between the upward price momentum and the actual structure of liquidity flows. The MACD Histogram, recorded at -1.80, reflects a divergence between the MACD line and its signal line, pointing towards a possible moderation of the upward momentum. These indicators suggest that the morning's bullish movement, although spectacular in appearance, is accompanied by mixed technical signals regarding the sustainability of the progression.
